Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update

B Achieved $18.5 million in first quarter of 2026 net product revenues for IBTROZI® (taletrectinib); majority of the approximately 200 patients started on IBTROZI in…
posteditor
posteditor
Articles: 17424

Other News